Lauren Stopfer

Executive Director, Proteomics & Innovation Aethon Therapeutics

Seminars

Wednesday 17th September 2025
Overcoming KRAS Inhibitor Resistance with T Cell Engagers Against Synthetic & Canonical pMHC Targets
4:00 pm
  • Engineering bispecific T cell engagers to selectively target KRAS covalent inhibitor–modified (haptenated) pMHCs with high affinity, specificity, and demonstrated in vitro/in vivo activity
  • Structural and functional insights reveal cross-HLA binding and the molecular basis of target recognition, supporting broad patient applicability
  • Expanding to canonical pMHC targets to address pan/multi/mutation-specific KRAS inhibitor resistance and KRAS-WT amplification
Lauren Stopfer, Executive Director, Proteomics & Innovation, Aethon Therapeutics
View all Speakers
View Event Brochure